Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx Prices $16.5M Public Offering

NEW YORK – Epigenetics firm VolitionRx said on Thursday that it has priced a planned public offering of 13 million shares of common stock at $1.27 per share, with expected gross proceeds of $16.5 million.

The Henderson, Nevada-based company said that it has also granted the underwriters of the offering a 30-day option to purchase an additional 1.95 million shares at the offering price.

Freedom Capital Markets is acting as the bookrunning manager of the offering and Bancroft Capital is acting as co-manager.

The offering is expected to close on or around June 5. During late morning trading on the New York Stock Exchange, shares of VolitionRx were down around 6 percent at $1.45.

VolitionRx is developing blood-based diagnostics based on its core Nu.Q nucleosome quantification platform. These include ones for cancer and various conditions associated with NETosis, a form of cell death characterized by the release of neutrophil extracellular traps (NETs) that trap and kill bacteria and viral particles.

The company said it will use the proceeds of the offering for R&D, clinical studies, product commercialization, working capital, and general corporate purposes.

Earlier this year, the company closed an $8.7 million public offering.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.